Assessment of the Clinical and Ultrasound Response to Apremilast by Clinical Evaluation and by a Joint-periarticular-nail Ultrasound Index in Patients With Active Psoriatic Arthritis
Latest Information Update: 28 Dec 2022
Price :
$35 *
At a glance
- Drugs Apremilast (Primary)
- Indications Psoriatic arthritis
- Focus Therapeutic Use
- Acronyms APREMILAST
- 14 Nov 2022 Status changed from recruiting to completed, as per results presented at the ACR Convergence 2022.
- 14 Nov 2022 Results assessing the safety and efficacy of Apremilast presented at the ACR Convergence 2022.
- 19 Jun 2019 Status changed from not yet recruiting to recruiting.